Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05896696 · ClinicalTrials.gov registry record · NA
Efficacy and Safety of the BeShape One Device for Non-invasive Waist Circumference Reduction
A NA study of Dermatological Non-Disease, sponsored by BeShape Technologies.
- Completed
- Registry status
- NA
- Development phase
- 81
- Enrollment target
- 2
- Study locations
NCT05896696: Completed NA study of Dermatological Non-Disease, sponsored by BeShape Technologies.
NCT05896696 is a NA study of Dermatological Non-Disease that has completed, run by BeShape Technologies. The registered enrollment target is 81 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05896696, a NA study of Dermatological Non-Disease, has completed, sponsored by BeShape Technologies.
- COMPLETED
- Registry status
- NA
- Development phase
- 81 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical trial is to evaluate the safety and efficacy of the BeShape One device for non-invasive waist circumference reduction in adults between the ages of 18 and 65. The main question\[s\] it aims to answer are: * reduction in waist circumference following treatment with the BeShape One device at the final 6 and 12-week follow-up visits compared to baseline * Subject improvement and satisfaction * Investigator satisfaction * Subject comfort/pain level Participants will undergo a single treatment with the BeShape One device at the Baseline visit and will return for two follow up visits at 6 and 12 weeks post treatment. Researchers will compare the results at the follow up visits to Baseline.
Primary Outcome
Waist circumference change (in cm) following BeShape treatment at the final 12 week follow-up visit compared to baseline.
Conditions Studied
Interventions
- DEVICE BeShape One
Study Locations (2)
Illinois
- Chicago Cosmetic Surgery and Dermatology - Chicago
Other
- Centro Poliklinika - Vilnius
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2022-04-28 |
| Est. Completion | 2023-04-27 |
| Phase | NA |
What the finished NCT05896696 record still lists
NCT05896696 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Dermatological Non-Disease appearing as the primary indexed condition, and to 1 intervention - of which BeShape One is the first listed.
NCT05896696 reports a single indexed study location in Illinois, Other.
Frequently Asked Questions
What is clinical trial NCT05896696 about?
NCT05896696 is a clinical study titled "Efficacy and Safety of the BeShape One Device for Non-invasive Waist Circumference Reduction". The goal of this clinical trial is to evaluate the safety and efficacy of the BeShape One device for non-invasive waist circumference reduction in adults between the ages of 18 and 65. The main question\[s\] it aims to answer are: * reduction in waist circumference following treatment with the BeSh...
What is the current status of trial NCT05896696?
This trial is currently completed. It is a NA study. The enrollment target is 81 participants. The study started on 2022-04-28. Estimated completion is 2023-04-27.
What conditions does trial NCT05896696 study?
This clinical trial studies the following conditions: Dermatological Non-Disease.
What interventions are being tested in trial NCT05896696?
The interventions under investigation include: BeShape One (DEVICE).
Who is sponsoring clinical trial NCT05896696?
This trial is sponsored by BeShape Technologies, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05896696 being conducted?
This trial has 2 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dermatological Non-Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05896696's enrollment target sits among peer trials
81 992nd of 2000 higher than 1,007 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI